Aadi Bioscience Past Earnings Performance

Past criteria checks 0/6

Aadi Bioscience's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 31% per year.

Key information

-17.0%

Earnings growth rate

19.2%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate31.0%
Return on equity-89.6%
Net Margin-246.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Aadi Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:3350 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2425-62360
30 Jun 2424-65400
31 Mar 2424-69440
31 Dec 2324-66450
30 Sep 2323-63450
30 Jun 2322-62440
31 Mar 2319-62420
31 Dec 2215-61400
30 Sep 2211-63390
30 Jun 227-136360
31 Mar 223-119270
31 Dec 211-111190
30 Sep 2114-8790
30 Jun 2115-220
31 Mar 2115-620
31 Dec 2015-420
31 Dec 191-1320

Quality Earnings: 3350 is currently unprofitable.

Growing Profit Margin: 3350 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 3350 is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.

Accelerating Growth: Unable to compare 3350's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3350 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 3350 has a negative Return on Equity (-89.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies